The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor-specific MHC class II upregulation associated with response to anti-PD-L1 therapy in patients with urothelial cancer.
 
İlayda Hasakioğulları
Employment - CellCarta
 
Mark Kockx
Leadership - CellCarta
Stock and Other Ownership Interests - CellCarta
 
Bernadett Szabados
Honoraria - Ellipses Pharma; Ipsen; Merck; Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Matthew Young
No Relationships to Disclose
 
Thomas Powles
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; CellCarta; Exelixis; Genentech; Gilead Sciences; GlaxoSmithKline; Ipsen; JJ Innovative Medicine; Merck; MSD; Natera; Novartis; Pfizer; Roche; Seagen; Takeda
Research Funding - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; CellCarta; Exelixis; Genentech; Gilead Sciences; GlaxoSmithKline; Ipsen; JJ Innovative Medicine; Merck; MSD; Natera; Novartis; Pfizer; Roche; Seagen; Takeda
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; CellCarta; Exelixis; Genentech; Gilead Sciences; GlaxoSmithKline; Ipsen; JJ Innovative Medicine; Merck; MSD; Natera; Novartis; Pfizer; Roche; Seagen; Takeda